References
- Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population. The GEM study. Neurology 2000;55:624–9
- Dowson A, Jagger S. The UK migraine patient survey: quality of life and treatment. Curr Med Res Opin 1999;15:241–53
- Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression. A population-based case-control study. Neurology 2000;55:629–35
- World Health Organization. World health report. Mental health: new understanding, new hope. Geneva: WHO; 2001
- Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57
- Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–8
- Cottrell CK, Drew JB, Waller SE, Holroyd KA, Brose JA, O’Donnell FJ. Perceptions and needs of patients with migraine: a focus group study. J Fam Pract 2002;51:142–7
- Rasmussen BK. Epidemiology of headache. Cephalalgia 2001;21:774–7
- Visser W, Jaspers N, de Vriend R, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264–9
- Couturier E, Bomhof M, Knuistingh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302–8
- MacGregor E, Hackshaw A. Prevalence of migraine on each day of the menstrual cycle in women not using hormonal treatments. Neurology 2004; [in press]
- Rains JC, Penzien DB, Martin VT. Migraine and women’s health. J Am Med Womens Assoc 2002;57:73–8
- MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the Global Migraine and Zolmitriptan Evaluation Survey. Headache 2003;43:19–26
- World Health Alliance Website http://www.ihaveaheadache.com
- Gobel H. Paper-pencil tests for retrospective and prospective evaluation of primary headaches on the basis of the IHS criteria. Headache 1994;34:564–8
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1–96
- Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine assessment score in a population-based sample of headache sufferers. Cephalalgia 1999;19:107–14
- Peters M, Huijer Abu-Saad H, Vydelingum V, Dowson A, Murphy M. Patients’ decision-making for migraine and chronic daily headache management. A qualitative study. Cephalalgia 2003;23:833–41
- Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638–45
- MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia 1990;10:305–10
- MacGregor EA, Igarashi H, Wilkinson M. Headaches and hormones: subjective versus objective assessment. Headache Quarterly 1997;8:126–36
- Dowson A, Syrett N, Charlesworth B. Patients with migraine prefer zolmitriptan ODT over conventional sumatriptan tablet and rizatriptan ODT. Neurology 2003;60(Suppl 1):495
- Charlesworth BR, Dowson AJ, Purdy A. Speed of onset and efficacy of zolmitriptan nasal spray on the acute treatment of migraine. CNS Drugs 2003;17:653–67
- Aschoff J, Gawel M, Lee J, Charlesworth B, May A, on behalf of the REALIZE study group. Zolmitriptan nasal spray is highly efficacious and very fast acting in the treatment of acute migraine in a real-life setting: results from phase I of the REALIZE study. Cephalalgia 2003;23: 711